Skip to main content
HairCited

Treatments for androgenetic alopecia and alopecia areata: current options and future prospects.

V M Meidan, E Touitou
Review Drugs 2001 48 인용
PubMed DOI
<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'pmid\u003D11217871'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

연구 유형
Review
대상 집단
Androgenetic alopecia and alopecia areata patients
중재
Treatments for androgenetic alopecia and alopecia areata: current options and future prospects. Minoxidil, finasteride, spironolactone, steroids
대조군
None
일차 결과
Hair loss treatment outcomes
효과 방향
Positive
비뚤림 위험
Unclear

Abstract

Androgenetic alopecia and alopecia areata are common disorders of the hair follicle which may heavily influence self esteem and self image. Androgenetic alopecia is caused by the heightened sensitivity of scalp follicles to dihydro- testosterone whereas alopecia areata is induced by an autoimmune reaction. Current drug treatment approaches include the use of regrowth stimulators such as topical minoxidil and oral finasteride for androgenetic alopecia, as well as topical minoxidil, dithranol (anthralin), corticosteroids, contact sensitisers, and psoralen plus ultraviolet A irradiation (PUVA) therapy for alopecia areata. Combination regimens are also proposed. However, extreme cases of either type of alopecia do not generally respond well to these existing treatments. For this reason, new therapeutic strategies are directed towards both improving the targeting of existing agents, as well as the development of novel hypertrichotic modalities.

요약

New therapeutic strategies are directed towards both improving the targeting of existing agents, as well as the development of novel hypertrichotic modalities for androgenetic and alopecia areata.

Used In Evidence Reviews

Similar Papers